Spreadsheet: 27470e15-4040-4eb1-9447-b0ce78ff093f
Sheet: TAB46NATPROVID

 | Estimated Vaccination Coverage* Among Children 19-35 Months of Age By Provider Facility Type^ and by State and Local Area -- US, National Immunization Survey, Q1/2010-Q4/2010†
[NAME] | Total | Public | Private | Mixed | Other
3+DTaP¥ | 95.0±0.6 | 94.6±1.6 | 96.9±0.7 | 97.8±1.0 | 91.4±1.7
4+DTaP‡ | 84.4±1.0 | 77.8±4.2 | 87.1±1.2 | 88.9±2.6 | 80.4±2.4
3+Polio§ | 93.3±0.7 | 93.7±1.7 | 94.7±0.9 | 96.5±1.3 | 90.2±1.8
1+MMRll | 91.5±0.7 | 91.8±1.9 | 92.6±0.9 | 94.0±2.0 | 89.4±1.8
3+Hib¶ | 90.4±0.9 | 89.1±2.4 | 92.3±1.2 | 93.9±1.5 | 86.4±2.1
Hib-PS** | 92.2±0.8 | 90.9±2.1 | 94.1±1.1 | 95.7±1.3 | 88.4±1.9
Hib-FS†† | 66.8±1.3 | 56.4±4.6 | 70.0±1.7 | 68.9±3.5 | 64.3±2.9
3+HepB‡‡ | 91.8±0.7 | 92.4±2.4 | 92.5±0.9 | 96.4±1.1 | 89.4±1.8
[NAME] dose§§ | 64.1±1.3 | 66.9±4.3 | 61.9±1.7 | 79.3±3.0 | 60.2±3.3
1+Varllll | 90.4±0.8 | 89.8±3.2 | 92.0±1.0 | 92.7±2.2 | 87.8±1.9
3+PCV¶¶ | 92.6±0.8 | 90.4±2.9 | 94.2±1.0 | 96.3±1.3 | 90.1±1.8
4+PCV*** | 83.3±1.0 | 76.4±3.8 | 85.7±1.3 | 87.0±2.5 | 80.7±2.4
2+HepA††† | 49.7±1.4 | 46.7±4.4 | 50.3±1.8 | 50.5±3.8 | 50.8±3.1
Rotavirus‡‡‡ | 59.2±1.4 | 47.3±4.5 | 62.6±1.7 | 61.4±3.6 | 56.6±3.2
4:3:1§§§ | 82.0±1.1 | 77.0±4.2 | 84.2±1.3 | 86.5±2.7 | 78.3±2.5
4:3:1:3llllll | 78.8±1.2 | 74.3±4.3 | 80.9±1.5 | 83.5±2.9 | 74.8±2.6
4:3:1:3-PS¶¶¶ | 80.3±1.1 | 75.4±4.3 | 82.4±1.5 | 85.1±2.8 | 76.3±2.6
4:3:1:4-FS**** | 62.2±1.3 | 54.1±4.5 | 64.9±1.7 | 65.1±3.6 | 59.6±2.9
4:3:1:3:3:1€ | 74.9±1.2 | 70.9±4.4 | 76.4±1.6 | 79.7±3.1 | 71.9±2.7
4:3:1:0:3:1ς | 77.8±1.1 | 73.5±4.4 | 79.3±1.4 | 82.6±3.0 | 75.3±2.6
4:3:1:3:3:1-PS€€ | 76.3±1.2 | 72.0±4.4 | 77.8±1.5 | 81.3±3.1 | 73.4±2.6
4:3:1:4:3:1-FSςς | 59.2±1.3 | 51.3±4.5 | 61.3±1.7 | 62.5±3.7 | 57.4±3.0
4:3:1:3:3:1:4€€€ | 70.2±1.3 | 65.1±4.5 | 71.6±1.6 | 75.7±3.2 | 67.5±2.8
4:3:1:0:3:1:4ςςς | 72.7±1.2 | 67.0±4.5 | 74.1±1.5 | 78.5±3.2 | 70.5±2.7
4:3:1:3:3:1:4-PS€€€€ | 71.5±1.2 | 66.1±4.5 | 73.0±1.6 | 77.3±3.2 | 69.0±2.8
4:3:1:4:3:1:4-FSςςςς | 56.6±1.3 | 48.4±4.4 | 58.4±1.7 | 60.6±3.7 | 55.1±3.0
 | * Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588 or (CI half width) >10. Estimates presented as point estimate (%) ± 95% Confidence Interval.
 | ^ Self-reported by provider. Public provider includes public health clinics and community health centers.  Private provider includes private clinics, HMOs and group practices.  Mixed provider includes more than one type of provider.  Other provider includes  all other types of providers such as hospitals, military facilities, and unknown responses.
 | † Children in the Q1/2010-Q4/2010 National Immunization Survey were born from January 2007 through July 2009.
 | ¥  3 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT).
 | ‡ 4 or more doses of DTaP.
 | § 3 or more doses of any poliovirus vaccine.
 | ll 1 or more doses of measles-mumps-rubella vaccine.
 | ¶ 3 or more doses of Haemophilus influenzae type b (Hib) vaccine.
 | ** Primary series Hib: ≥2 or ≥3 doses of Haemophilus influenzae type b (Hib), depending on brand type.
 | †† Full series Hib:  ≥3 or ≥4 doses of Hib vaccine depending on product type received (includes primary series plus the booster dose).
 | ‡‡ 3 or more doses of hepatitis B vaccine.
 | §§ 1 or more doses of hepatitis B vaccine administered between birth and age 3 days.
 | llll 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness.
 | ¶¶ 3 or more doses of pneumococcal conjugate vaccine (PCV).
 | *** 4 or more doses of PCV.
 | ††† 2 or more doses of Hepatitis A vaccine.
 | ‡‡‡ ≥2 or ≥3 doses of [NAME] vaccine, depending on product type received (≥2 doses for Rotarix® [RVI] or ≥3 doses for RotaTeq® [RV5]).
 | §§§ 4 or more doses of DTaP, 3 or more doses of poliovirus vaccine, and 1 or more doses of any MMR vaccine.
 | llllll 4:3:1 plus 3 or more doses of Hib vaccine of any type.
 | ¶¶¶ 4:3:1 plus the primary series Hib.
 | ****  4:3:1 plus the full series Hib.
 | € 4:3:1 plus 3 or more doses of Hib vaccine of any type, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ς 4:3:1 plus 3 or more doses of HepB vaccine and 1 or more doses of varicella vaccine. Hib vaccine is excluded.
 | €€ 4:3:1 plus primary series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ςς 4:3:1 plus full series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | €€€ 4:3:1 plus ≥3 doses of Hib vaccine of any type, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςς  4:3:1 plus 3 or more doses of HepB vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.  Hib vaccine is excluded.
 | €€€€ 4:3:1 plus primary series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςςς 4:3:1 plus full series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.